Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;118:773-784
doi: 10.1161/CIRCULATIONAHA.108.787630
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Brown, M. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, M. J.
Related Collections
Right arrow Other hypertension

(Circulation. 2008;118:773-784.)
© 2008 American Heart Association, Inc.


New Drugs and Technologies

Aliskiren

Morris J. Brown, FMedSci

From the University of Cambridge, Cambridge, UK.

Correspondence to Morris J. Brown, FMedSci, FAHA, Clinical Pharmacology Unit, Box 110, Addenbrookes Hospital, Cambridge, CB3 9AA, UK. E-mail m.j.brown{at}cai.cam.ac.uk

Aliskiren is the first orally active inhibitor of renin to be approved for clinical use as an antihypertensive agent. The development program has established that at the licensed doses of 150 mg and 300 mg, there are dose-related falls in blood pressure comparable to those seen with other major classes of antihypertensive drugs and that these falls are associated with a placebo level of side effects. Aliskiren was found to be effective either as monotherapy or in combination with drugs from the other major classes. As expected, there was a greater benefit from adding aliskiren to natriuretic drugs than to other blockers of the renin system. However, there was also some consistent benefit from dual renin blockade. Aliskiren is likely to be of most value in patients uncontrolled by, or intolerant of, other classes. Rational understanding of the renin system will maximize its value, for instance, by encouraging greater use of natriuretic agents in patients with resistant hypertension to render their hypertension renin dependent. Whether there are cardiovascular benefits other than blood pressure control in blocking the renin system remains to be demonstrated. It is hoped that long-term outcome studies with aliskiren will finally allow this question to be answered.


Key Words: aliskiren • renin • renin inhibitor